The coronavirus pandemic has heightened the already critical need in the US for OTC access to daily oral contraceptives, reproductive health researchers, clinicians and advocacy groups contend in urging the Food and Drug Administration to prioritize completing a review on making the drugs available OTC.
The letter, signed by nearly 120 researchers, clinicians and advocacy representatives, notes a 2020 Guttmacher Institute survey found one...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?